Mohammad Vaziri’s Post

Case of defective coaptation of the tricuspid valve leaflets, leading to incomplete closure and significant regurgitation and RV dysfunction with groslly dilated IVC measuring 42mm. This patient underwent Coronary Artery Bypass Grafting (CABG) in 1999 and has a known history of: - Decompensated Chronic Liver Disease (DCLD) - Chronic Kidney Disease (CKD) - Anemia - hypertension

In this study that our colleagues Karen Appiah, Ph.D and Evi Zhuleku conducted, we used German Claims data provided by AOK PLUS German administrative claims dataset to evaluate cardiovascular disease (CVD) comorbidity profiles among COVID-19 patients before and after hospitalization.   Prior CVDs were frequently observed in hospitalized COVID-19 patients, and the comorbidity and healthcare burden markedly increased following COVID-19 hospitalizations.    CVD events and related comorbidities mainly observed during follow-up included hypertension, heart failure, arrythmia, and disorders of lipoprotein metabolism. Significantly higher mean cardiovascular risk scores and higher mean healthcare resource utilization was observed during follow-up.   The results have been presented in ISPOR EUROPE.

NEW HELP FOR HEART DISEASE....... Since the 1950s, medical scientists have understood that high cholesterol is can contribute to coronary artery disease (CAD) by clogging the arteries with plaque. More recently, they learned that chronic inflammation in the arteries is another key risk factor. Now, two large multinational clinical trials have shown that colchicine, a drug that's already used to treat other inflammatory conditions such as gout, is also useful for preventing heart attack, stoke and cardiovascular death in people with CAD. When added to standard treatments such as statins, it reduced the risk of these complications by as much as 31%. The FDA recently approved low-dose colchicine for this purpose, making it the first medication that tackles cardiovascular disease by specifically targeting inflammation. .........From Readers Digest March/April 2024 issue

Want to stay updated on the cardiovascular risks associated with JAKis in #RheumatoidArthritis? Goldman et al. analysed data from the FDA Adverse Event Reporting System to assess the cardiovascular risks associated with JAKis in patients with rheumatoid arthritis. This study aimed to understand the real-world safety profile of these treatments. The study found that JAKis were associated with increased reporting of venous thromboembolism, stroke, and ischemic heart disease. These adverse events were most frequent in the first year of treatment. The findings highlight the importance of cardiovascular monitoring in patients treated with JAKis. For a detailed summary of the deck, visit the IMID Forum. https://ow.ly/3C9150Sn6L0 #RheumatoidArthritis #CardiovascularHealth #JAKInhibitors #ClinicalResearch #IMIDForum

Inverse Relationship Between Urinary Sodium Excretion and Cardiovascular Risk in Hypertensive Patients: A Surprising Discovery “Because sodium reduction can lower blood pressure (BP), at least in some hypertensive individuals, and because the reduction of BP is beneficial, it has been assumed that a diet low in sodium would also reduce subsequent cardiovascular disease (CVD). As a result, a sodium-reduced diet is widely recommended, particularly for hypertensive patients, as both a primary and an adjunctive treatment. In the present study, we examined the relation of urinary sodium (UNaV) excretion alone to subsequent morbidity and mortality in 2937 treated hypertensive subjects. We now report that in the group as a whole and particularly in men, baseline UNaV was *inversely* related to subsequent MI, cardiovascular morbidity and mortality, and all-cause mortality but not to non-CVD mortality.”

The truth about cardiovascular diseases is that, at some point, a fair amount of people will have a form of cardiovascular compromise ranging from clinically asymptomatic to critical states. It is imperative to delay this onset by effectively predicting and reducing cardiovascular risk through lifestyle modification and drug therapy. The latest addition to risk reduction therapy is low dose colchicine. It is recommended for individuals at risk of future cardiovascular events or death. This risk is typically determined by elevated levels of highly sensitive CRP (hs-CRP), which has now been proven to be a better predictor of cardiovascular risk than Low Density Lipoprotein (LDL) Because vascular inflammation is a forerunner of major adverse cardiovascular events(MACE), colchicine is the first specific anti-inflammatory drug demonstrated to reduce the risk for myocardial infarction (MI), stroke, coronary revascularization, and cardiovascular death in adult patients with established atherosclerotic disease or with multiple risk factors for cardiovascular disease. Colchicine is gotten from the autumn crocus plant and has been used for thousands of years in Egypt for gouty arthritis and today we use it for cardiovascular protection. Speak to your physician about your cardiovascular risk and if colchicine is appropriate for you. #cardiovascularhealth #nigeria #prevent #atherosclerosis

Did you know that NAFLD is closely linked to cardiovascular disease (#CVD)? 🫀 Recent studies have found a significant association between non-alcoholic fatty liver disease (#NAFLD) and #CardiovascularDisease. It has been estimated that up to 25% of the US population is affected by NAFLD, making it a growing health problem. 📊 NAFLD is an important independent risk factor for cardiovascular disease, with patients with #NAFLD being more likely to develop atherosclerosis, coronary artery disease, and other cardiovascular complications. 🫀❗ According to research, this is because #NAFLD shares many of the same risk factors as cardiovascular disease, including high blood pressure, high cholesterol, and metabolic syndrome. Even after adjusting for traditional cardiovascular risk factors, research has shown #NAFLD to be an independent risk factor for the development of #CardiovascularDisease. 🏥 This is where Liposcale® comes in. ✅ Our non-invasive diagnostic test is based on a high-performance technology that allows comprehensive analysis of the profile of lipoproteins present in the bloodstream. The information extracted from the profile of lipoproteins is essential in the clinic to diagnose the risk of CVD. By detecting these warning signs early, patients can take steps to manage their risk factors and prevent complications before they become serious. 🔬 At CIMA Sciences, LLC, we are committed to advancing noninvasive diagnostic technology and improving access to care for patients with NAFLD and other health conditions. By detecting and treating #NAFLD earlier we can help reduce the risk of cardiovascular disease and improve patient outcomes. Contact us today to learn more about Liposcale® and our commitment to advancing healthcare at info@cimasciences.com.⚕️ #CIMASciences #NAFLD #NonInvasiveTesting #CardiovascularDisease #Healthcare

👉Inclisiran and cardiovascular events: a comprehensive review of efficacy, safety, and future perspectives ☝️Inclisiran is a promising treatment for lowering LDL-C levels in people at high risk of atherosclerotic cardiovascular disease. It is a practical and well tolerated option for those who struggle to stick to medication regimes because of its twice-yearly dosage schedule and a good safety profile. Is a significant advancement in lipid-lowering medication and could improve patient outcomes Kausik Ray MD FMedSci https://lnkd.in/dmBm_Put

The Diabetic Lung....why it matters..... Reduced lung function of diabetic patients characterized by low forced expiratory volume in one second (FEV1) is two to three times faster than that of normal nonsmoking subjects. Reduced forced vital capacity and lung dynamic compliance, peripheral airway obstruction as well as reduced pulmonary diffusing capacity for carbon monoxide (CO) has been reported in diabetic patients. Pulmonary autonomic neuropathy in diabetic patients, results in an impaired ventilatory response to hypoxia. sympathetic neuropathy impairs pulmonary function, resulting in ventilatory response abnormalities to central and peripheral stimuli. In this line, parasympathetic neuropathy may cause an increase in airway caliber at baseline. Pulmonary autonomic neuropathy reduces mucociliary clearance and prone the lung to the infections. Reduced respiratory muscle strength due to defective muscle metabolism and neuropathy of the phrenic nerve promote respiratory muscle dysfunction in diabetic patients https://lnkd.in/gGGcuxz4

🌟 Highlighting the Importance of Early Screening for Cardiovascular Autonomic Neuropathy (CAN) in Diabetes Management 🌟   A recent study has confirmed the significant role of Cardiovascular Autonomic Neuropathy (CAN) as a predictor of kidney function decline in both Type 1 and Type 2 diabetes. This research, involving a large population of well-characterized individuals, strengthens the existing literature linking CAN with the progression of renal failure in diabetic patients. - https://lnkd.in/gz4aVKhC -   The findings underscore the critical need for early and proactive screening for CAN. Recognizing and treating CAN in its early, even asymptomatic, stages can be crucial in preventing the progression of Diabetic Kidney Disease (DKD) and other severe complications.   At MDE Technologies, we are committed to advancing diabetes management. Our innovative solution, Cardiologic, offers a simple and user-friendly way to screen for CAN. By integrating early screening into routine diabetes care, we can help reduce the risk of more severe complications like DKD and improve overall patient outcomes.   Let's work together to prioritize early detection and prevention. 🌐 Learn more about Cardiologic and how it can make a difference: https://lnkd.in/gdnpKrPK   #DiabetesManagement #CAN #DiabeticKidneyDisease #HealthcareInnovation #Cardiologic #EarlyDetection #PatientCare